期刊文献+

洛匹那韦混合胶束的制备与大鼠口服生物利用度研究 被引量:3

Preparation of lopinavir mixed micelles and study on oral bioavailability in rats
下载PDF
导出
摘要 目的制备洛匹那韦混合胶束(lopinavir mixed micelles,LPV-MMs),并通过大鼠灌胃给药评价其药动学和口服生物利用度。方法以聚乙烯己内酰胺-聚醋酸乙烯酯-聚乙二醇接枝共聚物(polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer,Soluplus^(■))和聚乙二醇1000维生素E琥珀酸酯(D-alpha-tocopheryl polyethylene glycol 1000 succinate,TPGS)作为载体材料,采用溶剂蒸发-薄膜水化法制备LPV-MMs,通过单因素研究方法确定了LPV-MMs的处方组成,并用透射电镜观察了LPV-MMs的微观形态;考察了LPV-MMs在不同pH介质中的药物释放速率;采用Caco-2细胞单层模型评估LPV原料药和LPV-MMs的跨膜转运特性;通过大鼠灌胃给药比较了LPV原料药和LPV-MMs的药动学和口服生物利用度。结果经实验研究确定LPV-MMs的处方中Soluplus^(■)和TPGS的质量比为70∶10,制备的LPV-MMs的粒径分布为(48.3±5.9)nm,Zeta电位为(1.38±0.04)mV,在透射电镜下可观察到LPV-MMs呈球形分布,粒径大小分布均匀;LPV-MMs在不同pH介质中的药物释放速率无明显差异;LPV-MMs能够有效提高药物的跨膜转运能力;大鼠体内药动学结果显示,将LPV制备成混合胶束后可显著提高药物的达峰浓度,增加药物口服生物利用度。结论本研究以Soluplus^(■)和TPGS作为载体材料,将洛匹那韦制备成混合胶束,显著提高了药物的跨膜转运能力,增加了药物的口服生物利用度。 Objective To prepare lopinavir mixed micelles(LPV-MMs),and evaluate their pharmacokinetics and oral bioavailability in rats.Methods The polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer(Soluplus^(■))and D-alpha-tocopherol polyethylene glycol succinate(TPGS)were used as carrier materials to prepare LPV-MMs.The formulation composition of LPV-MMs was determined by single factor experiment.The microscopic morphology of LPV-MMs was observed under transmission electron microscope.The drug release rates of LPV-MMs in different pH media were investigated.The Caco-2 cell monolayer model was used to evaluate the transmembrane transport characteristics of LPV substance and LPV-MMs.The pharmacokinetics and oral bioavailability of LPV substance and LPV-MMs were compared by intragastric administration in rats.Results The experimental results determined that the mass ratio of Soluplus^(■)and TPGS in the formulation of LPV-MMs was 70∶10.The particle size distribution of LPV-MMs was(48.3±5.9)nm,and the Zeta potential was(1.38±0.04)mV.The LPV-MMs had the spherical morphology with uniform particle size in the transmission electron microscope.There was no significant difference in the drug release rate of LPV-MMs in different pH media.LPV-MMs could effectively improve the transmembrane transport ability.The pharmacokinetics in rats showed that LPV-MMs could significantly increase the peak concentration and improve the oral bioavailability of the drug.Conclusion In this study,Soluplus^(■)and TPGS are used as carrier materials to prepare lopinavir mixed micelles,which significantly improves the transmembrane transport ability and increases the oral bioavailability of lopinavir.
作者 赵小义 冯华 朱钰叶 ZHAO Xiaoyi;FENG Hua;ZHU Yuye(Xianyang Vocational and Technical College,Xianyang 712000,China)
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2022年第7期773-779,共7页 Journal of Shenyang Pharmaceutical University
关键词 洛匹那韦 混合胶束 药动学 跨膜转运 生物利用度 lopinavir mixed micelles pharmacokinetics transmembrane transport bioavailability
  • 相关文献

参考文献6

二级参考文献63

  • 1MU L, FENG SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol) : PLGA nanoparticles containing vitamin E TPGS [ J ]. J Control Release, 2003,86(1) :33 -48.
  • 2MU L, FENG SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio [J]. PharmRes, 2003, 20(11) :1864 -1872.
  • 3KRASAVAGE WJ, TERHAAR CJ. d-α-Toeophetyl poly( ethylene glycol) 1000 succinate: acute toxicity, subchronic feeding, reproduction and teratologic studies in the rat [ J ]. J Agric Food Chem, 1977,25 (2) :273 - 278.
  • 4MU L, FENG SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol) [ J ]. J Control Release, 2002, 80 ( 1 - 3 ) : 129 - 144.
  • 5ZHANG Z,FENG SS. Nanoparticles of poly (lactide)/vitamin E TPGS copolymer for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug release[J]. Biomaterials, 2006, 27 (2) : 262 - 270.
  • 6ISMAILOS G, REPPAS C, MACHERAS P. Enhancement of cyclosporine A solubility by d-α-tocopheryl-polyethylene-glycol- 1000 succinate(TPGS) [J]. Eur J Pharm Scl, 1994, 1(5): 269 - 271.
  • 7YU L, BRIDGERS A, POLLI J, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability [ J ]. Pharm Res, 1999, 16 (12) : 1812 - 1817.
  • 8DAI WG, DONG LC,Li S, et al. DongCombination of Pluronic/ Vitamin E TPGS as a potential inhibitor of drug precipitation [ J ]. Int JPharm,2008, 355(1 -2) : 31 -37.
  • 9HUNTER J, HIRST BH, SIMMONS NL. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers [ J]. Pharm Res, 1993, 10 (5) :743 -749.
  • 10KRISHNA R, MAYER LD. Multidrug resistance (MDR) in cancer, mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs[J]. Eur J Pharm Sci, 2000, 11(4) : 265 -283.

共引文献57

同被引文献36

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部